1. Prange, AJ Jr., The pharmacology and biochemistry of depression. Dis New Syst. 1964;5:217–221.
2. Schildkraut, JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965;122:509–522.
3. Koslow, SH, Maas, JW, Bowden, CL et al. , CSF and urinary biogenic amines and metabolites in depression and mania: a controlled, univariate analysis. Arch Gen Psychiatry. 1983;40:999–1010.
4. Redmond, DE, Katz, MM, Maas, JW et al. , Cerebrospinal fluid amine metabolites: relationships with behavioral measurements in depressed, manic, and healthy control subjects. Arch Gen Psychiatry. 1986;43:938–947.
5. Beckmann, H, Goodwin, FK. Urinary MHPG in subgroups of depressed patients and normal controls. Neuropsychobiology. 1980;6:91–100.
6. Roy, A, Pickar, D, Linnoila, M, Potter, WZ. Plasma norepinephrine level in affective disorders: relationship to melancholia. Arch Gen Psychiatry. 1985;42:1181–1185.
7. Veith, R, Lewis, N, Linares, O et al. , Sympathetic nervous system activity in major depression: basal and desipramine-induced alterations in plasma norepinephrine kinetics. Arch Gen Psychiatry. 1994;51:411–422.
8. Charney, DS. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry. 1998;59(Suppl 14):11–14.
9. Salomon, R, Miller, HL, Krystal, JH et al. , Lack of behavioral effects of monoamine depletion in healthy subjects. Biol Psychiatry. 1997;41:58–64.
10. Delgado, PL. Depression: the case for a monoamine deficiency. J Clin Psychiatry. 2000;61(Suppl 6):7–11.
11. Berman, RM, Narasimhan, M, Miller, H et al. , Transient depressive relapse induced by catecholamine depletion. Arch Gen Psychiatry. 1999;56:395–403.
12. Hornykiewicz, O. Brain noradrenaline and schizophrenia. In: JM, Van Ree, SW, Matthysse, eds. Progress in Brain Research. Vienna: Elsevier Science Publisher; 1986:29–39.
13. Weinberger, DR. Schizophrenia and the frontal lobe. TINS. 1988;11:367–370.
14. Archer, T, Ogren, SO, Johansson, G, Ross, SB. DSP4-induced two-way active avoidance impairment in rats: involvement of central and not peripheral noradrenaline depletion. Psychopharmacology. 1982;76:303–309.
15. Mason, ST. Noradrenaline in the brain: progress in theories of behavioural function. Prog Neurobiol. 1981;16:263–303.
16. Plaznik, A, Pucilowski, O, Kostowski, W et al. , Rotational behavior produced by unilateral ventral noradrenergic bundle lesions: evidence for a noradrenergic-dopaminergic interaction in the brain. Pharmacol Biochem Behav. 1982;17:619–622.
17. Lake, CR, Steinberg, DE, van Kammen, DP et al. , Schizophrenia: elevated cerebrospinal fluid norepinephrine. Science. 1980;207:331–333.
18. Sternberg, DE, Van Kammen, DP, Lake, CR et al. , The effect of pimozide on CSF norepinephrine in schizophrenia. Am J Psychiatry. 1981;138:1045–1050.
19. Van Kammen, DP, Antelman, S. Impaired noradrenergic transmission in schizophrenia? [Review]. Life Sci. 1984;34:1403–1413.
20. Rich, CL, Young, D, Fowler, RC. San Diego suicide study. Arch Gen Psychiatry. 1986;43:577–582.
21. Stockmeier, CA, Jurjus, G. Monoamine receptors in postmortem brain tissue in suicide. In: Agam, G, RH, Belmaker, Everall, I, eds. The Postmortem Brain in Psychiatric Research. Kluwer Academic Publishers; Dortrecht, the Netherlands; 2001: in press.
22. De Paermentier, F, Mauger, JM, Lowther, S et al. , Brain alpha-adrenoceptors in depressed suicides. Brain Res. 1997;757:60–68.
23. Arango, V, Ernsberger, P, Syed, AF, Mann, JJ. Quantitative autoradiography of a1 and a2 adrenergic receptors in the cerebral cortex of controls and suicide vietims. Brain Res. 1993;630:271–282.
24. Gross-Isseroff, R, Dillon, KA, Fieldust, SJ, Biegon, A. Autoradiographic analysis of alpha 1-noradrenergic receptors in the human brain postmortem. Effect of suicide [published erratum appears in Arch Gen Psychiatry 1991 Sep;48(9):862]. Arch Gen Psychiatry: 1990;47:1049–1053.
25. Crow, TJ, Cross, AJ, Cooper, SJ et al. , Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides. Neuropharmacology. 1984;23:1561–1569.
26. Klimek, V, Rajkowska, G, Luker, SN et al. , Brain noradrenergic receptors in major depression and schizophrenia. Neuropsychopharmacology. 1999;21:69–81.
27. Ferrier, IN, McKeith, IG, Cross, AJ et al. , Postmortem neurochemical studies in depression. Ann N Y Acad Sci. 1986;487:128–142.
28. Meana, JJ, Garcia-Sevilla, JA. Increased a2-adrenoceptor density in the frontal cortex of depressed suicide victims. J Neural Transm. 1987;70:377–381.
29. Meana, JJ, Barturen, F, Garcia-Sevilla, JA. Alpha2-adrenoceptors in the brain of suicide victims: increased receptor density associated with major depression. Biol Psychiatry. 1992;31:471–490.
30. Sirota, P. Is schizophrenia an autoimmune disease. Isr J Med Sci. 1990;26:694–697.
31. Joyce, JN, Lexow, N, Jin Kim, S et al. , Distribution of beta-adrenergic receptor subtypes in human post-mortem brain: Alterations in limbic regions of schizophrenics. Synapse. 1992;10:228–246.
32. Bennett, JP, Enna, SJ, Bylund, DB et al. , Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry. 1979;36:927–934.
33. De Paermentier, F, Cheetham, SC, Crompton, MR et al. , Brain beta-adrenoceptor binding sites in antidepressant-free depressed suicide victims. Brain Res. 1990;525:71–77.
34. Mann, JJ, Stanley, M, McBride, PA, McEwen, BS. Increased serotonin2 and b-adrenergic receptor binding in the frontal cortices of suicide victims. Arch Gen Psychiatry. 1986;43:954–959.
35. Arango, V, Ernsberger, P, Marzuk, PM et al. , Autoradiographic demonstration of increased serotonin 5-HT2 and B-adrenergic receptor binding sites in the brain of suicide victims. Arch Gen Psychiatry. 1990;47:1038–1047.
36. Biegon, A, Israeli, M. Regionally selective increases in b-adrenergic receptor density in the brains of suicide victims. Brain Res. 1988;442:199–203.
37. Gross-Isseroff, R, Israeli, M, Biegon, A. Autoradiographic analysis of [3H] desmethylimipramine binding in the human brain postmortem. Brain Res. 1988;456:120–126.
38. Arora, RC, Meltzer, HY. Laterality and 3H-imipramine binding: studies in the frontal cortex of normal controls and suicide victims. Biol Psychiatry. 1991;29:1016–1022.
39. Stanley, M, Virgilio, J, Gershon, S. Tritiated imipramine binding sites are decreased in the frontal cortex of suicides. Science. 1982;216:1337–1339.
40. Grote, SS, Moses, SG, Robins, E et al. , A study of selected catecholamine metabolizing enzymes: a comparison of depressive suicides and alcoholic suicides with controls. J Neurochem. 1974;23:791–802.
41. Mann, J. J. and Stanley, M.postmortem monoamine oxidase enzyme kinetics in the frontal cortex of suicide victims and controls. Acta Psychiatr Scand. 1984;69:135–139.
42. Maeztu, AI, Ballesteros, J, Callado, LF et al. , The density of monoamine oxidase B sites is not altered in the postmortem brain of alcoholics. Alcohol Clin Exp Res. 1997;21:1479–1483.
43. Gottfries, CG, Oreland, L, Wiberg, A, Winblad, B. Lowered monoamine oxidase activity in brains from alcoholic suicides. J Neurochem. 1975;25:667–673.
44. Callado, LF, Meana, JJ, Grijalba, B et al. , Selective increase of a2A-adrenoceptor agonist binding sites in brains of depressed suicide victims. J Neurochem. 1998;70:1114–1123.
45. Garcia, S, Escriba, PV, Ozaita, A et al. , Up-regulation of immunolabeled alpha2Aadrenoceptors, Gi coupling proteins, and regulatory receptor kinases in the prefrontal cortex of depressed suicides. J Neurochem. 1999;72:282–291.
46. Ordway, GA, Widdowson, PS, Smith, KS, Halaris, A. Agonist binding to a2-adrenoceptors is elevated in the locus coeruleus from victims of suicide. J Neurochem. 1994;63:617–624.
47. Ordway, GA, Schenck, JE, Dilley, GE et al. , Increased p-[125I]iodoclonidine binding to a2-adrenoceptors in the locus coeruleus in major depression. Soc Neurosci Abs. 1999;25:2139
48. Klimek, V, Stockmeier, CA, Overholser, JC et al. , Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci. 1997;17:8451–8458.
49. Ordway, GA, Farley, IJ, Dilley, GE et al. , Quantitative distribution of monoamine oxidase A in brainstem monoamine nuclei is normal in major depression. Brain Res. 1999;847:71–79.
50. Ordway, GA, Smith, KS, Haycock, JW. Elevated tyrosine hydroxylase in the locus coeruleus of suicide victims. J Neurochem. 1994;62:680–685.
51. Zhu, M-Y, Klimek, V, Dilley, GE et al. , Elevated levels of tyrosine hydroxylase in the locus coeruleus in major depression. Biol Psychiatry. 1999;46:1275–1286.
52. Biegon, A, Fieldust, S. Reduced tyrosine hydroxylase immunoreactivity in locus coeruleus of suicide victims. Synapse. 1992;10:79–82.
53. Baumann, B, Danos, P, Diekmann, S et al. , Tyrosine hydroxylase immunoreactivity in the locus coeruleus is reduced in depressed non-suicidal patients but normal in depressed suicide patients. Eur Arch Psychiatry Clin Neurosci. 1999;249:212–219.
54. Arango, V, Undenvood, MD, Mann, JJ. Fewer pigmented locus coeruleus neurons in suicide victims: preliminary results. Biol Psychiatry. 1996;39:112–120.
55. Danysz, W, Kostowski, W, Hauptmann, M. Evidence for the locus coeruleus involvement in desipramine action in animal models of depression. Pol J Pharmacol Pharm. 1985;7:855–864.
56. Wolfe, BB, Harden, TK, Sporn, JR, Molinoff, PB. Presynaptic modulation of beta adrenergic receptors in rat cerebral cortex after treatment with antidepressants. J Pharmacol Exp Ther. 1978;207:446–457.
57. Biegon, A, Rainbow, TC. Localization and characterization of [3H]desmethylimipramine binding sites in rat brain by quantitative autoradiography. J Neurosci. 1983;3:1069–1076.
58. Richards, JG, Saura, J, Ulrich, J, DaPrada, M. Molecular neuroanatomy of monoamine oxidases in human brainstem. Psychopharmacology. 1992;106 (Suppl):S21–23.
59. Cortes, R, Soriano, E, Pazos, A et al. , Autoradiography of antidepressant binding sites in the human brain: localization using [3H]imipramine and [3H]paroxetine. Neuroscience. 1988;27:473–496.
60. Hrdina, PD, Foy, B, Hepner, A, Summers, RJ. Antidepressant binding sites in the brain: autoradiographic comparison of [3H]paroxetine and [3H]imipramine localization and relationship to serotonin transporter. J Pharmacol Exp Ther. 1990;52:410–418.
61. Kovachich, GB, Frazer, A, Aronson, CE. Effect of chronic administration of antidepressants on alpha 2-adrenoceptors in the locus coeruleus and its projection fields in rat brain determined by quantitative autoradiography. Neuropsychopharmacology. 1993;8:57–65.
62. Melia, KR, Rasmussen, K, Terwilliger, RZ et al. , Coordinate regulation of the cyclic AMP system with firing rate and expression of tyrosine hydroxylase in the rat locus coeruleus: effects of chronic stress and drug treatments. J Neurochem. 1992;58:494–502.
63. Weiss, JM, Goodman, PA, Losito, BG et al. , Behavioral depression produced by an uncontrollable stressor: Relationship to norepinephrine, dopamine, and serotonin levels in various regions of rat brain. Brain Res Rev. 1981;3:167–205.
64. U'Prichard, DC, Bechtel, WD, Rouot, BM, Snyder, SH. Multiple apparent alphanoradrenergic receptor binding sites in rat brain: effect of 6-hydroxydopamine. Mol Pharmacol. 1979;16:47–60.
65. Gross, G, Gothert, M, Glapa, U et al. , Lesioning of serotoninergic and noradrenergic nerve fiber's of the rat brain does not decrease binding of 3H-clonidine and 3H-rauwolscine to cortical membranes. Naunyn-Schmiedeherg's Arch Pharmacol. 1985;328:229–235.
66. Cubells, JF, Kim, KS, Baker, H et al. , Differential in vivo regulation of mRNA encoding the norepinephrine transporter and tyrosine hydroxylase in rat adrenal medulla and locus coeruleus. J Neurochem. 1995;65:502–509.
67. Lee, C-M, Javitch, JA, Snyder, SH. Recognition sites for norepinephrine uptake: regulation by neurotransmitter. Science. 1983;220:626–629.
68. Johnson, EW, Wolfe, BB, Molinoff, PB. Regulation of subtypes of B-adrenergic receptors in rat brain following treatment with 6-hydroxydopamine. J Neurosci. 1989;9:2297–2305.
69. Ordway, GA, Gambarana, C, Frazer, A. Quantitative autoradiography of central beta adrenoceptor subtypes: comparison of the effects of chronic treatment with desipramine or centrally administered l-isoproterenol. J Pharmacol Exp Ther. 1988;247:379–389.
70. Ordway, GA, Klimek, V, Mann, JJ. Neurocircuitry of mood disorders. In: Anonymous Psychopharmacology: The Fifth Generation of Progress. 2001: in press.